Shenzhen RuiJin Pharmaceutical Co.,Ltd 86-188-06592208 Gavin@hgh-steroid.com
Avodart Dutasteride CAS 164656-23-9

Avodart Dutasteride CAS 164656-23-9

  • High Light

    Avodart Dutasteride

    ,

    164656-23-9 Avodart Dutasteride

  • Other Name
    Avodart
  • CAS 
    164656-23-9
  • Molecular formula
    C27H30F6N2O2
  • Molecular weight
    528.53
  • Melting Point
    42-250℃
  • Flash Point
    28.954°C
  • Email
    Gavin@hgh-steroid.com
  • Whatsapp
    +08618806592208
  • Place of Origin
    China
  • Brand Name
    RuiiJin
  • Certification
    ISO9001
  • Model Number
    164656-23-9
  • Minimum Order Quantity
    10g
  • Price
    Negotiable
  • Packaging Details
    Disguised package or according to your requirement
  • Delivery Time
    Within 48hours after payment
  • Payment Terms
    Western union and moneygram,Bank transfer,Bitcoin,
  • Supply Ability
    3000kg/month

Avodart Dutasteride CAS 164656-23-9

Avodart Dutasteride CAS:164656-23-9

 

Dutasteride Quick Detail:

 

Dutasteride (Avodart ) CAS:164656-23-9
Other name: Avodart
1. CAS register number: 164656-23-9
2. Molecular formula: C27H30F6N2O2
3. Molecular weight: 528.53
4. Assay: 99%

Avodart Dutasteride CAS 164656-23-9 0
5. Appearance: White crystalline powder

Dosage:
Monotherapy: 0.5 mg once daily.
Combination with tamsulosin: 0.5 mg once daily and tamsulosin 0.4 mg once daily.
Dosing considerations: Swallow whole. May take with or without food.

 

 

Specifications:

 

Product Name: Dutasteride
CAS No.: 164656-23-9 Quantity 10kg
Rep Date 20150310 Batch NO. 20150315
MFG. Date 20150310 Expiry Date 20170314

 

Item Specifications Results
Description:
Color White or almost white Crystalline Powder almost white Crystalline Powder
Identification IR and UV Complies
Physical:
Loss on drying ≤0.5% 0.15%
Residue on ignition ≤0.1% Complies
Related substance ≤1.0% 0.33%
Melting Point 246.0~252.0°C 248.5~250°C
Chemical:
Heavy metals ≤10ppm 8ppm
Assay:
Dutasteride 97.0%~103.0% 99.8%
Conclusion The results conforms With Enterprise Standard.

 

 

How should Dutasteride be used?

 

Dutasteride comes as a capsule to take by mouth. It is usually taken once a day with or without food. Take dutasteride at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take dutasteride exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the capsules whole; do not open chew, or crush them.

Your symptoms may improve after you have taken dutasteride for 3 months, but it may take 6 months or longer for you to see the full benefit of dutasteride. Talk to your doctor about how you are feeling during your treatment.

Dutasteride may control your symptoms but will not cure your condition. Continue to take dutasteride even if you feel well. Do not stop taking dutasteride without talking to your doctor.

 

 

How to use Anastrozole / Arimidex

 

  • 1. For men:

Anastrozole / Arimidex has been tested for reducing estrogens, including estradiol, in men. Excess estradiol in men can cause benign prostatic hyperplasia, gynecomastia, and symptoms of hypogonadism. It can also contribute to increased risk of stroke, heart attack, chronic inflammation, prostate enlargement and prostate cancer. Some athletes and body builders use Anastrozole / Arimidex as part of their steroid cycle to reduce and prevent symptoms of excess estrogen–gynecomastia, emotional lability and water retention. Study data suggests dosages of 0.5 mg to 1 mg a day reduce serum estradiol approx. 50% in men, which differs in postmenopausal women.

 

  • 2. For children:

Anastrozole / Arimidex may be used off-label in children with precocious puberty, or children with pubertal gynecomastia.Following the onset of puberty, the epiphyseal plate begins to close due to an increased amount of estrogen production escaping local metabolism and spreading to the circulatory system. It is shown to help slow this process, and increase adult height prediction in adolescent males treated with protein-based peptide hormones for the treatment of growth hormone deficiency.

 

1, Increasing the time before the cancer comes back in those who experience recurrence
2, Reducing the risk of the cancer spreading to other parts of the body
3, Reducing the risk of a new cancer developing in the other breast